

CITATION REPORT

List of articles citing

Tadalafil for the Treatment of Lower Urinary Tract Symptoms in Japanese Men with Benign Prostatic Hyperplasia: Results from a 12-week Placebo-controlled Dose-finding Study with a 42-week Open-label Extension

DOI: 10.1111/j.1757-5672.2012.00144.x

LUTS: Lower Urinary Tract Symptoms, 2012, 4, 110-9.

Source: <https://exaly.com/paper-pdf/52554679/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
34	Re: Response to Advantages of self-tailored mesh for vaginal prolapse. <i>International Journal of Urology</i> , 2012 , 19, 1047-1048	2.3	1
33	Advantages of self-tailored mesh for vaginal prolapse. <i>International Journal of Urology</i> , 2012 , 19, 494-5	2.3	1
32	Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men. <i>International Journal of Urology</i> , 2013 , 20, 193-201	2.3	66
31	Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action. <i>International Journal of Urology</i> , 2013 , 20, 28-39	2.3	43
30	Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil. <i>World Journal of Men's Health</i> , 2013 , 31, 193-207	6.8	37
29	The Efficacy and Safety of Tadalafil 5 mg Once Daily in Korean Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: An Integrated Analysis. <i>World Journal of Men's Health</i> , 2014 , 32, 28-35	6.8	11
28	Editorial comment to Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea. <i>International Journal of Urology</i> , 2014 , 21, 676	2.3	
27	Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea. <i>International Journal of Urology</i> , 2014 , 21, 670-5	2.3	34
26	Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: analyses of data pooled from three randomized, double-blind, placebo-controlled studies. <i>International Journal of Urology</i> , 2015 , 22, 378-84	2.3	21
25	Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action. <i>Therapeutic Advances in Urology</i> , 2015 , 7, 249-64	3.2	17
24	Effects of Sildenafil, a Phosphodiesterase Type 5 Inhibitor, on the Primary Single Afferent Activity of the Rat Bladder. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2017 , 9, 57-61	1.9	2
23	Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2017 , 9, 176-186	1.9	6
22	Tadalafil for male lower urinary tract symptoms improves endothelial function. <i>International Journal of Urology</i> , 2017 , 24, 206-210	2.3	13
21	Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥5 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies. <i>BJU International</i> , 2017 , 119, 793-803	5.6	19
20	Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2017 , 71, 570-581	19.2	36
19	Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study). <i>LUTS: Lower Urinary Tract Symptoms</i> , 2018 , 10, 76-83	1.9	4
18	Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia. <i>International Journal of Urology</i> , 2018 , 25, 240-245	2.3	6

17	Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. <i>The Cochrane Library</i> , 2018 , 11, CD010060	5.2	8
16	Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post-Marketing Surveillance Study. <i>World Journal of Men's Health</i> , 2018 , 36, 161-170	6.8	9
15	Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. <i>BJU International</i> , 2019 , 124, 27-34	5.6	4
14	Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized study. <i>Central European Journal of Urology</i> , 2019 , 72, 44-50	0.9	7
13	Voiding behavior and chronic pelvic pain in two types of rat nonbacterial prostatitis models: Attenuation of chronic pelvic pain by repeated administration of tadalafil. <i>Prostate</i> , 2019 , 79, 446-453	4.2	6
12	Efficacy and safety of tadalafil 5mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase III, randomized, double-blind, parallel, placebo- and tamsulosin-controlled study. <i>International Journal of Urology</i> , 2019 , 26, 102-109	2.3	11
11	Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review. <i>Aging Male</i> , 2019 , 22, 1-11	2.1	21
10	Treatment of experimentally induced benign prostatic hyperplasia with Tadalafil and castration in dogs. <i>Theriogenology</i> , 2020 , 142, 236-245	2.8	4
9	Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED. <i>Current Urology Reports</i> , 2020 , 21, 56	2.9	11
8	Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study. <i>International Journal of Clinical Practice</i> , 2020 , 74, e13530	2.9	3
7	Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α -Blockers and 5-Alpha Reductase Inhibitors. <i>Uro</i> , 2021 , 1, 82-98		
6	Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia. <i>Central European Journal of Urology</i> , 2014 , 67, 167-77	0.9	9
5	Efficacy and Safety of 12-week Monotherapy With Once Daily 5 mg Tadalafil for Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: Evidence-based Analysis. <i>Frontiers in Medicine</i> , 2021 , 8, 744012	4.9	0
4	Real-World Safety and Effectiveness of Tadalafil in Patients with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Japanese Post-Marketing Surveillance Study. <i>Journal of Pragmatic and Observational Research</i> , 2020 , 11, 45-54	7.4	2
3	Comparative Efficacy of Different Drugs for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Bayesian Network Meta-Analysis.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 763184	5.6	
2	Efficacy of tadalafil on symptom-specific bother in men with lower urinary tract symptoms. <i>LUTS: Lower Urinary Tract Symptoms</i> ,	1.9	1
1	Discontinuation Rates of Tadalafil Alone and in Combination with α -Blockers in the Treatment of Male Lower Urinary Tract Symptoms with or without Coexisting Erectile Dysfunction: A Systematic Review and Meta-Analysis. 2022 , 2022, 1-14		0